News | July 03, 2025
Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
A triple-action Formula for comprehensive respiratory relief
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The inspection concluded with zero Form 483 observations
Subscribe To Our Newsletter & Stay Updated
